Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.44 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 8/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | CTSE | P14091 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10297468 | 1.00 | REN (0.44) | RENAPLNRCAPN1CTSBKMT2A | |
| SCHEMBL10297453 | 0.96 | REN (0.44) | RENAPLNRCAPN1CTSBKMT2A | |
| SCHEMBL17029372 | 0.96 | REN (0.44) | RENAPLNRCAPN1CTSBKMT2A | |
| SCHEMBL10297425 | 0.96 | REN (0.44) | RENAPLNRCAPN1CTSBKMT2A | |
| SCHEMBL29463850 | 0.90 | REN (0.40) | RENAPLNRCMA1 | |
| SCHEMBL10297438 | 0.87 | ELANE (0.42) | RENCMA1 | |
| SCHEMBL21581232 | 0.87 | ELANE (0.42) | RENCMA1 | |
| SCHEMBL10297466 | 0.87 | ELANE (0.42) | RENCMA1 | |
| SCHEMBL29463845 | 0.87 | ELANE (0.42) | RENCMA1 | |
| SCHEMBL10297463 | 0.86 | REN (0.53) | RENCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2955233-A1 | Proteinase K inhibitors, methods and compositions therefor | Life Technologies Corporation (US) | 2015-12-16 | — | — | EP | disclosed |
| US-9114104-B2 | Proteinase K inhibitors, methods and compositions therefor | Life Technologies Corporation (US) | 2015-08-25 | — | — | US | disclosed |
| EP-2367954-B1 | PROTEINASE K INHIBITORS, METHODS AND COMPOSITIONS THEREFOR | LIFE TECHNOLOGIES CORP (US) | 2015-02-18 | — | — | EP | disclosed |
| US-20130004941-A1 | PROTEINASE K INHIBITORS, METHODS AND COMPOSITIONS THEREFOR | Life Technologies Corporation (US) | 2013-01-03 | — | — | US | disclosed |
| US-8211637-B2 | Proteinase K inhibitors, methods and compositions therefor | Life Technologies Corporation (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100159482-A1 | PROTEINASE K INHIBITORS, METHODS AND COMPOSITIONS THEREFOR | Life Technologies Corporation (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130004941-A1 | PROTEINASE K INHIBITORS, METHODS AND COMPOSITIONS THEREFOR | CPSF7, CTSL, CTSK | REN 564/4885APLNR 2918/4885CAPN1 854/4885 |
| US-20100159482-A1 | PROTEINASE K INHIBITORS, METHODS AND COMPOSITIONS THEREFOR | CPSF7, CTSL, CTSK | REN 564/4885APLNR 2918/4885CAPN1 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.